February 15, 2022
February 15, 2022
Six feasibility programs underway for oral tablet formulations developed with Enteris’ Peptelligence® and ProPerma® technology platforms Boonton, NJ, February 15, 2022 — Enteris BioPharma, Inc., a biotechnology […]
December 20, 2021
December 20, 2021
Boonton, NJ, December 20, 2021 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
December 9, 2021
December 9, 2021
Fourth milestone payment triggered by successful completion of process technology transfer related to the development of Oral KORSUVA™ Dallas, TX, December 09, 2021 — SWK Holdings Corporation […]
November 2, 2021
November 2, 2021
Paper Examines the Opportunities and Challenges in Working with High Potency APIs Boonton, NJ, November 02, 2021 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug […]
October 26, 2021
October 26, 2021
Boonton, NJ, October 26, 2021 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
October 13, 2021
October 13, 2021
Boonton, NJ, October 13, 2021 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
September 29, 2021
September 29, 2021
Data indicates optimized Peptelligence® oral leuprolide formulation delivers comparable or greater drug levels than subcutaneous or depot injection Boonton, NJ, September 29, 2021 — Enteris BioPharma, […]
KNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MOREKNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MORE
